A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection - Full Text View

Purpose

Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg). Dose escalation or repetition will be governed by pre-specified safety and activity rules. Subjects will be confined on days 1-3 and/or days 8-10. Follow-up visits are required periodically through day 43. Subjects with sustained reductions in HbsAg will be requested to return for additional follow-up follow-up visits at 3 and 6 months post last dose. Study procedures involve blood draws for pharmacokinetic, pharmacodynamic, virologic, and safety assessments

Condition	Intervention	Phase
Hepatitis B	Drug: Single Ascending Dose (SAD) Cohorts GS-9620 Drug: Multiple Ascending Dose (MAD) Cohorts GS-9620	Phase 1

Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment
Official Title:	A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection

Resource links provided by NLM:

MedlinePlus related topics: Hepatitis Hepatitis A Hepatitis B

Drug Information available for: Recombinant Hepatitis B vaccine Hepatitis A Vaccines

U.S. FDA Resources

Further study details as provided by Gilead Sciences:

Primary Outcome Measures:

Assessment of adverse events in single and multiple oral doses of GS-9620 [ Time Frame: Periodically Day 1 to 6 months ] [ Designated as safety issue: Yes ]
Assessments include adverse events, laboratory abnormalities, 12-lead ECG abnormalities and interval measurements, and vital signs measurements

Secondary Outcome Measures:

Assessment of plasma drug concentrations of GS-9620 using non-compartmental methods [ Time Frame: Day 1 and Day 8 ] [ Designated as safety issue: No ]
SAD and MAD Cohorts:serial blood samples will be collected on Day 1 at 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 48, and 96 hours post-dose.

Mad Cohorts: serial blood samples will also be collected on Day 8 at 0 (pre-dose), , 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.
Measurement of pharmacodynamic markers (cytokines and ISGs) [ Time Frame: Days 1, 2, 3, 5, 8 ] [ Designated as safety issue: No ]
SAD Cohorts: Whole blood and serum for PD assessments (RNA and cytokine analysis) will be drawn on Day 1 at pre-dose, 8, 24 and 48 hours post-dose, and on Days 5 and Day 8

MAD Cohorts: Whole blood and serum for PD assessments (RNA and cytokine analysis) will be drawn on Day 1: Pre-dose and 8 hours Postdose, Day 2, Day 3, and Day 5 Day 8: Pre-dose and 8 hours Post-dose, Day 9, 10, 12, and Day 15
Reduction of HBV viral load from baseline [ Time Frame: Screening, Baseline, Day 8 or 15 ] [ Designated as safety issue: No ]
SAD cohort: HBsAg+ levels will be drawn at Day 1: Pre-dose, Day 2, 3, 5, 8 and both Follow-up Visits.

MAD cohorts: HBsAg+ levels will be drawn at Day 1: Pre-dose, Day 2, 3, 5, Day 8: Pre-Dose, 9, 10, 15, and both Follow-Up Visits.

Estimated Enrollment:	60
Study Start Date:	April 2012
Estimated Study Completion Date:	July 2013
Estimated Primary Completion Date:	July 2013 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 0.3mg GS-9620	Drug: Single Ascending Dose (SAD) Cohorts GS-9620 This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
Experimental: 1mg GS-9620	Drug: Single Ascending Dose (SAD) Cohorts GS-9620 This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
Experimental: 2mg GS-9620	Drug: Single Ascending Dose (SAD) Cohorts GS-9620 This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
Experimental: 4mg GS-9620	Drug: Single Ascending Dose (SAD) Cohorts GS-9620 This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
Experimental: 0.3mg GS-9620 QW x 2 doses	Drug: Multiple Ascending Dose (MAD) Cohorts GS-9620 This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
Experimental: 1mg GS-9620 QW x 2 doses	Drug: Multiple Ascending Dose (MAD) Cohorts GS-9620 This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
Experimental: 2mg GS-9620 QW x 2 doses	Drug: Multiple Ascending Dose (MAD) Cohorts GS-9620 This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
Experimental: 4mg GS-9620 QW x 2 doses	Drug: Multiple Ascending Dose (MAD) Cohorts GS-9620 This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Chronic HBV infection for ≥ 6 months
Currently on treatment with TDF ≥ 3 months prior to screening
HBsAg ≥ 250 IU/mL
HBV DNA < LLoQ for at least 3 months prior to screening
Absence of extensive bridging fibrosis (Metavir 3 or greater)or cirrhosis
BMI 18-33kg/m^2
Creatinine clearance ≥ 70mL/min

Exclusion Criteria:

Co-infection with HCV, HDV or HIV
History of Gilberts disease
Laboratory parameters not within defined thresholds for leukopenia, neutropenia, anemia, thrombocytopenia, TSH, or other evidence of hepatic decompensation
Diagnosis of autoimmune disease, poorly controlled diabetes mellitus, significant psychiatric illness, severe COPD, malignancy, hemoglobinopathy, retinal disease, or patients who are immunosuppressed
Evidence of hepatocellular carcinoma

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01590654

Contacts

Contact: Uri Lopatin, MD	650-522-5120	Uri.Lopatin@gilead.com
Contact: Benedetta Massetto, MD	650-522-5075	Benedetta.Massetto@gilead.com

Hide Study Locations

Locations

United States, Arizona
Mayo Clinic Hospital	Not yet recruiting
Phoenix, Arizona, United States, 85054
Contact 480-342-2536
United States, California
University of California Antiviral Research Center (AVRC)	Recruiting
San Diego, California, United States, 92103
Contact 619-543-8080
United States, Indiana
Indiana University Medical Center	Recruiting
Indianapolis, Indiana, United States, 46202-5121
Contact 317-278-2586
United States, Louisiana
Tulane University Health Sciences Center	Recruiting
New Orleans, Louisiana, United States, 70112
Contact 504-988-1619
United States, Maryland
National Institute of Allergy and Infectious Diseases	Recruiting
Bethesda, Maryland, United States, 20892
Contact 301-451-4647
United States, Massachusetts
Beth Israel Deaconess Medical Center	Recruiting
Boston, Massachusetts, United States, 022154
Contact 617-632-1051
United States, Michigan
Henry Ford Health System	Recruiting
Detroit, Michigan, United States, 48202
Contact 313-916-6049
United States, Missouri
Kansas City Gastroenterology and Hepatology	Recruiting
Kansas City, Missouri, United States, 64131
Contact 816-361-0055
United States, New York
Weill Cornell Medical College	Recruiting
New York, New York, United States, 10021
Contact 832-355-8966
CliniLabs	Recruiting
New York, New York, United States, 10019
Contact 646-215-6400
United States, Ohio
University Hospitals Case Medical Center	Recruiting
Cleveland, Ohio, United States, 44106
Contact 216-844-3878
United States, Texas
Baylor College of Medicine	Recruiting
Houston, Texas, United States, 77030
Contact 646-962-4742
United States, Utah
University of Utah	Recruiting
Salt Lake City, Utah, United States, 84132
Contact 801-587-9060
Australia, New South Wales
Nepean Hospital, Department of ID	Not yet recruiting
Kingswood, New South Wales, Australia, 2747
Contact +61247343466
Australia, Queensland
Royal Brisbane and Women's Hospital	Recruiting
Herston, Queensland, Australia, 4029
Contact +610736361757
Australia, Victoria
Monash University, Dept. of Medicine	Recruiting
Clayton, Victoria, Australia, 3168
Contact +61395941487
Alfred Hospital, Department of Gastroenterology	Recruiting
Melbourne, Victoria, Australia, 3004
Contact +61390762069
Australia, Western Australia
Royal Perth Hospital	Recruiting
Nedlands, Western Australia, Australia, 6009
Contact +610863825102
Canada, Alberta
University of Calgary, Heritage Medical Research Center	Recruiting
Calgary, Alberta, Canada, T2N 4Z6
Contact 1 (403) 210-3800
University of Alberta Hospital	Recruiting
Edmonton, Alberta, Canada, T6G 2B7
Contact 780-492-8602
Canada, Quebec
Algorithme Pharma, Inc.	Recruiting
Laval, Quebec, Canada, H7V 4B3
Contact 1 (450) 973-3155 ext: 2261
New Zealand
Aukland Clinical Studies	Recruiting
Grafton, Aukland, New Zealand, 1142
Contact +6493733474106

Sponsors and Collaborators

Gilead Sciences

More Information

No publications provided

Responsible Party:	Gilead Sciences
ClinicalTrials.gov Identifier:	NCT01590654 History of Changes
Other Study ID Numbers:	GS-US-283-0102
Study First Received:	April 30, 2012
Last Updated:	November 26, 2012
Health Authority:	United States: Food and Drug Administration Canada: Health Canada Australia: Department of Health and Ageing Therapeutic Goods Administration New Zealand: Medsafe

Keywords provided by Gilead Sciences:

Hepatitis
Hepatitis B
Hepatitis B Virus

HBV
GS-9620
TLR-7 Agonist

Additional relevant MeSH terms:

Hepatitis
Hepatitis A
Hepatitis B
Hepatitis, Chronic
Hepatitis B, Chronic
Hepatitis, Viral, Human
Encephalitis, Herpes Simplex
Virus Diseases
Liver Diseases
Digestive System Diseases
Enterovirus Infections

Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections
Encephalitis, Viral
Encephalitis
Central Nervous System Viral Diseases
Herpesviridae Infections
Central Nervous System Infections
Central Nervous System Diseases
Nervous System Diseases

ClinicalTrials.gov processed this record on May 23, 2013